Faculty

David T. Jones, M.D.

Clinical Studies

Development of an AI-driven, FDG-PET based approach to track disease progression and evolution to phenoconversion in progranulin mutation carriers Rochester, Minn.
The purpose of this study is to develop an AI-driven biomarker based on FDG-PET images to track longitudinal brain changes in asymptomatic (n = 10) and symptomatic (n = 10) GRN mutation carriers.
Longitudinal Early-onset Alzheimer's Disease Study Protocol (LEADS) Rochester, Minn., Jacksonville, Fla.
The purpose of this Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is designed to look at disease progression in individuals with early onset cognitive impairment . Clinical/cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset Alzheimer's Disease (EOAD) participants, (2) early onset non-Alzheimer's Disease (EO-nonAD) participants,and (3) cognitively normal (CN) control participants.

Mapping Brain States and Their Response to a Non-Pharmacologic Intervention Rochester, Minn.
The purpose of this study is to develop improved assessments and mappings of the large scale organization of the brain, and look at the possibilities of producing measurable change with non-drug intervention.
Robust Connectome-Based Biomarkers of Degenerating Brain Systems Across the Alzheimer’s Disease Spectrum Rochester, Minn.
This study is being done to learn more about specialized systems in the brain and how they relate to the disease processes in aMCI and AD.